Evan Lippman, Executive Vice President of Business Development at Teva Pharmaceutical Industries Ltd., filed a Form 4 on August 19, 2026, reporting the sale of 18,600 ordinary shares on August 17, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: Lippman disposed of 18,600 ordinary shares of Teva Pharmaceutical Industries Ltd. on August 17, 2026.
  • Weighted average price: The shares were sold at a weighted average price of $36.5748, with individual transactions ranging from $36.57 to $36.61, inclusive.
  • Post-transaction ownership: Following the sale, Lippman directly holds 25,591 ordinary shares.
  • 10b5-1 plan: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Lippman on May 16, 2026.
  • Security type: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share, according to the filing.

Lippman Share Sale Details Under Teva's 10b5-1 Plan

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Evan Lippman, EVP of Business Development at NASDAQ:TEVA (Teva Pharmaceutical Industries Ltd.), sold 18,600 ordinary shares on August 17, 2026. The filing indicates the transaction was made directly and bears transaction code "S," reflecting a sale. The form was signed by Dov Bergwerk as attorney-in-fact for Evan Lippman and dated August 19, 2026.

The filing discloses that the reported price of $36.5748 is a weighted average, and that the shares were sold across multiple transactions at prices ranging from $36.57 to $36.61, inclusive. The filing further states that Lippman "undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."

The transaction was carried out under a Rule 10b5-1 trading plan that Lippman adopted on May 16, 2026, as noted in the filing's explanation of responses. Following the reported sale, Lippman's direct beneficial ownership stands at 25,591 ordinary shares. No derivative securities transactions were reported in this filing.

What Was Disclosed

The Form 4 discloses that Teva's EVP of Business Development, Evan Lippman, sold 18,600 ordinary shares on August 17, 2026, at a weighted average price of $36.5748 per share under a pre-established 10b5-1 trading plan, retaining direct ownership of 25,591 shares.